Researcher Presents Promising Early Results on Color Cascade Testing Uptake at ACMG Meeting

Apr 15, 2018

|

CHARLOTTE, NC (GenomeWeb) – An early analysis of data from the Color Genomics Color Family Testing Program suggests it is possible to get relatively robust uptake of cascade testing for hereditary cancer risk when cost is decreased and access is simplified.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Researcher Presents Promising Early Results on Color Cascade Testing Uptake at ACMG Meeting

To read the full story....

Breaking News

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

BioReference Settles False Claims, Kickback Allegations for $11.5M

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships